Chemically Induced Neuron Reprogramming via Small Molecule Cocktails
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current direct lineage reprogramming methods using viral vectors for converting non-neuronal cells into neuronal cells face challenges such as low efficiency and genomic integration concerns, which limit their therapeutic potential for neurodegenerative disorders.
Innovation Solution
A cocktail of small molecules, including cyclic adenosine monophosphate agonists, neurogenic small molecules, glycogen synthase kinase inhibitors, transforming growth factor β inhibitors, and BET family bromodomain inhibitors, is used to reprogram non-neuronal cells into neuron-like cells, bypassing the need for viral vectors and enhancing efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If viral vectors are used for direct lineage reprogramming, then cell fate conversion can be achieved, but low efficiency and genomic integration concerns arise
Solution Approach 1:
The patent replaces the mechanical/biological system of viral vector delivery with a chemical system using small molecule compounds. Instead of using viruses to deliver transcription factors, the invention uses small molecules (such as retinoic acid, dibutyryl cAMP, and other chemically defined compounds) to directly induce neuronal differentiation in non-neuronal cells, thereby eliminating genomic integration risks while achieving reprogramming
Solution Approach 2:
The patent introduces small molecule compounds as intermediaries that mediate the reprogramming process. These small molecules act as chemical mediators that can modulate cellular pathways and gene expression without requiring viral delivery, thus serving as a safe intermediary between the reprogramming goal and the cellular machinery
2Productivity
If viral vectors are used for direct lineage reprogramming, then cell fate conversion can be achieved, but technical challenges and high costs arise
Solution Approach 1:
The patent employs small molecule compounds that are inexpensive, chemically stable, and do not require complex delivery systems. These small molecules can be easily synthesized or obtained, are not immunogenic, and do not require the sophisticated viral vector systems, thereby reducing both cost and technical complexity while maintaining reprogramming efficiency
3Adaptability or versatility
If viral vectors are used for direct lineage reprogramming, then cell fate conversion can be achieved, but immunogenicity and standardization issues arise
Solution Approach 1:
The patent substitutes the biological viral delivery system with a chemical small molecule system. This replacement eliminates the immunogenicity associated with viral vectors and cellular therapies, as small molecules are not recognized by the immune system. Additionally, small molecules can be precisely dosed and standardized, improving therapeutic applicability
Data Source
AI summary
Cocktails of chemical inducers of neuron-like properties (CINP) is provided, which includes cAMP agonists, neurogenic small molecules, glycogen synthase kinase inhibitors, TGFβ receptor inhibitors, and BET family bromodomain inhibitors and optionally, a selective inhibitor of ROCK or p38 MAPK. These cocktails are used in a method of inducing neuron-like properties in partially or completely differentiated non-neuronal cells. The method includes contacting cells of a first type (non-neuronal) with the CINPs for a sufficient period of time to result in reprogramming the cell into cells of a second type having neuron-like characteristics (CiNs). Isolated chemically induced neurons (CiNs) can be used in a number of applications, including but not limited to cell therapy.